A Caltech Library Service

Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York

West, Anthony P., Jr. and Wertheim, Joel O. and Wang, Jade C. and Vasylyeva, Tetyana I. and Havens, Jennifer L. and Chowdhury, Moinuddin A. and Gonzalez, Edimarlyn and Fang, Courtney E. and Di Lonardo, Steve S. and Hughes, Scott and Rakeman, Jennifer L. and Lee, Henry H. and Barnes, Christopher O. and Gnanapragasam, Priyanthi N. P. and Yang, Zhi and Gaebler, Christian and Caskey, Marina and Nussenzweig, Michel C. and Keeffe, Jennifer R. and Bjorkman, Pamela J. (2021) Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York. Nature Communications, 12 . Art. No. 4886. ISSN 2041-1723. PMCID PMC8352861; PMC8077570. doi:10.1038/s41467-021-25168-4.

[img] PDF - Published Version
Creative Commons Attribution.

[img] PDF (April 22, 2021) - Submitted Version
Creative Commons Attribution Non-commercial No Derivatives.

[img] PDF - Supplemental Material
Creative Commons Attribution.

[img] PDF (Peer Review File) - Supplemental Material
Creative Commons Attribution.

[img] PDF (Reporting Summary) - Supplemental Material
Creative Commons Attribution.

[img] PDF (Description of Additional Supplementary Files) - Supplemental Material
Creative Commons Attribution.

[img] Plain Text (Supplementary Data 1) - Supplemental Material
Creative Commons Attribution.

[img] Plain Text (Supplementary Data 2) - Supplemental Material
Creative Commons Attribution.

[img] Plain Text (Supplementary Data 3) - Supplemental Material
Creative Commons Attribution.

[img] Archive (ZIP) (Supplementary Data 4) - Supplemental Material
Creative Commons Attribution.


Use this Persistent URL to link to this item:


Wide-scale SARS-CoV-2 genome sequencing is critical to tracking viral evolution during the ongoing pandemic. We develop the software tool, Variant Database (VDB), for quickly examining the changing landscape of spike mutations. Using VDB, we detect an emerging lineage of SARS-CoV-2 in the New York region that shares mutations with previously reported variants. The most common sets of spike mutations in this lineage (now designated as B.1.526) are L5F, T95I, D253G, E484K or S477N, D614G, and A701V. This lineage was first sequenced in late November 2020. Phylodynamic inference confirmed the rapid growth of the B.1.526 lineage. In concert with other variants, like B.1.1.7, the rise of B.1.526 appears to have extended the duration of the second wave of COVID-19 cases in NYC in early 2021. Pseudovirus neutralization experiments demonstrated that B.1.526 spike mutations adversely affect the neutralization titer of convalescent and vaccinee plasma, supporting the public health relevance of this lineage.

Item Type:Article
Related URLs:
URLURL TypeDescription CentralArticle ItemData ItemData ItemCode CentralDiscussion Paper Paper
Wertheim, Joel O.0000-0003-4882-5856
Vasylyeva, Tetyana I.0000-0002-9736-7022
Rakeman, Jennifer L.0000-0002-9464-7723
Barnes, Christopher O.0000-0003-2754-5951
Yang, Zhi0000-0001-8680-3784
Gaebler, Christian0000-0001-7295-8128
Caskey, Marina0000-0003-1727-8693
Nussenzweig, Michel C.0000-0003-0592-8564
Keeffe, Jennifer R.0000-0002-5317-6398
Bjorkman, Pamela J.0000-0002-2277-3990
Alternate Title:SARS-CoV-2 lineage B.1.526 emerging in the New York region detected by software utility created to query the spike mutational landscape
Additional Information:© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit Received 10 June 2021; Accepted 28 July 2021; Published 09 August 2021. We thank the Global Initiative on Sharing Avian Influenza Data (GISAID) and the originating and submitting laboratories for sharing the SARS-CoV-2 genome sequences; see Supplementary Data 4 for a list of sequence contributors. We thank Andrew Rambaut and Áine O’Toole for lineage designation. This work was supported by the Caltech Merkin Institute for Translational Research (P.J.B.). This work was supported, in whole or in part, by the Bill & Melinda Gates Foundation [grant INV-002143 to P.J.B.]. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. J.O.W. acknowledges funding from the National Institutes of Health (AI135992 and AI136056). T.I.V. is funded by a Branco Weiss Fellowship. M.C.N. is an HHMI Investigator. Data availability: The SARS-CoV-2 genomes generated in this study have been deposited in GenBank under accession codes MZ637509-MZ642234 (see Supplementary Data 1) and GISAID (see Supplementary Data 2 for a list of genomes used in phylogenetic analysis and Supplementary Data 3 for genomes used in geographic distribution analysis). The data analyzed as part of this project were obtained from the GISAID database and through a Data Use Agreement between NYC DOHMH and the University of California San Diego. Sequences analyzed by using the vdb tool were downloaded from GISAID. No personally identifying information were included as part of these analyses. Data for Fig. 5 are provided in Supplementary Tables 2 and 3. Code availability: The source code for the vdb program is available at the GitHub repository46: Author Contributions: A.P.W., J.O.W., J.L.H., T.I.V., H.H.L., S.H. and J.C.W. analyzed data. J.C.W., M.A.C., E.G. and H.H.L. performed genome sequencing and assembly. J.O.W. curated data. C.G., M. Caskey and M.C.N. provided clinical samples. P.N.P.G. and J.R.K. carried out experiments. A.P.W., C.O.B., Z.Y., S.H., S.S.D., C.E.F., T.I.V, J.L.H. and J.O.W. prepared figures. A.P.W., J.O.W., T.I.V., C.O.B., J.C.W. and S.H. wrote the manuscript with input from all co-authors. A.P.W., P.J.B., J.O.W., J.L.R. and S.H. supervised the study. Competing interests: P.J.B. is a co-inventor on a provisional application from the California Institute of Technology for the use of mosaic nanoparticles as coronavirus immunogens. M.C.N., P.J.B. and C.O.B. are co-inventors on provisional applications for several anti-SARS-CoV-2 monoclonal antibodies. J.O.W. has received funding from Gilead Sciences, LLC (completed) and the CDC (ongoing) via grants and contracts to his institution unrelated to this research. All other authors declare no competing interests. Peer review information: Nature Communications thanks the anonymous reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.
Group:COVID-19, Richard N. Merkin Institute for Translational Research
Funding AgencyGrant Number
Caltech Merkin Institute for Translational ResearchUNSPECIFIED
Bill and Melinda Gates FoundationINV-002143
Branco Weiss FellowshipUNSPECIFIED
Howard Hughes Medical Institute (HHMI)UNSPECIFIED
Subject Keywords:Epidemiology; SARS-CoV-2; Software; Viral infection
PubMed Central ID:PMC8352861; PMC8077570
Record Number:CaltechAUTHORS:20210216-123229308
Persistent URL:
Usage Policy:No commercial reproduction, distribution, display or performance rights in this work are provided.
ID Code:108067
Deposited By: Tony Diaz
Deposited On:16 Feb 2021 21:26
Last Modified:27 Aug 2021 16:34

Repository Staff Only: item control page